RAYMOND BROWN: Open Payments
NPI 1730313305 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$646 in 18 payments from 8 companies in 2025. Trend: 2023 $541 · 2024 $679 · 2025 $646
Food & beverage: $646
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 2 | $177 |
| E.R. Squibb & Sons, L.L.C. | 8 | $152 |
| Janssen Scientific Affairs, LLC | 1 | $149 |
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| ABBVIE INC. | 2 | $48 |
| Lundbeck LLC | 1 | $25 |
| Alkermes, Inc. | 1 | $24 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $16 |
Products named: INGREZZA, COBENFY, INVEGA SUSTENNA, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, ARISTADA, ABILIFY MAINTENA.
Industry payments across DC — which companies pay providers there.
